Welcome to our dedicated page for Well Health Tech news (Ticker: WHTCF), a resource for investors and traders seeking the latest updates and insights on Well Health Tech stock.
WELL Health Technologies Corp. reports developments across a Canadian outpatient healthcare platform, digital health software and related technology-enabled services. The company operates a large owned clinic network in Canada and reports recurring updates on patient visits, Canadian Patient Services, primary care and specialty care performance, acquisitions, clinic transformation activity and financial results.
WELL’s news also covers WELLSTAR healthcare technology products, including electronic medical records, AI-powered clinical tools, patient engagement, eReferral and IT managed services. Other recurring themes include HEALWELL AI, CYBERWELL cybersecurity services, virtual cardiology through CardiologyNow, partnerships for remote cardiac monitoring, conference participation and financing capacity for the company’s healthcare operations.
WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF), a digital health company, announced the approval of its Normal Course Issuer Bid (NCIB) by the Toronto Stock Exchange. This NCIB, renewing the previous one expired on June 4, 2024, allows WELL to purchase up to 6,154,501 common shares, representing approximately 2.5% of its 246,180,060 issued and outstanding shares, over the next 12 months. Purchases will be made on the open market through the TSX and Canadian alternative trading systems, with daily purchases capped at 209,016 shares. Shares acquired will be cancelled to facilitate an orderly market and improve shareholder value. Under the previous NCIB, the company acquired 119,400 shares at an average price of $3.70 per share. The new NCIB will be effective from June 10, 2024, to June 9, 2025.
WELL Health Technologies Corp. (WELL) reported record quarterly revenue of $231.6 million in Q1-2024, a 37% increase YoY, driven by acquisitions and organic growth of 13%. Adjusted EBITDA reached $28.3 million, a 6% increase from Q1-2023. Net Income was $19.6 million compared to a loss in Q1-2023. The company increased its guidance for 2024 revenue to $960-980 million and Adjusted EBITDA to $125-130 million. WELL also expects to improve FCFA2S by 30% in 2024.
WELL Health Technologies Corp. will announce its Fiscal First Quarter 2024 financial results on May 8, 2024. The company focuses on digital healthcare to improve health outcomes globally. The conference call will be hosted by CEO Hamed Shahbazi and CFO Eva Fong.
WELL and HEALWELL AI have launched the second-generation of WELL AI Decision Support (WAIDS) with advanced chronic disease screening capabilities. The tool identifies over 100 diseases and provides actionable clinical insights, aiding in chronic disease management in Canada, which costs an estimated $190 billion annually. The upgraded WAIDS now detects chronic diseases like chronic kidney disease, hypertension, and diabetes, offering risk stratification for patients. Dr. Michael Frankel, Chief Medical Officer of WELL, praised the tool for its effectiveness in providing key disease insights and risk assessments to physicians. HEALWELL AI's technology powers WAIDS, aiming to enhance decision-making in healthcare. The collaboration between WELL and HEALWELL AI continues to leverage data science and innovative technology to transform healthcare.
WELL Health Technologies announced a collaboration with Microsoft to accelerate healthcare's digital transformation. This partnership aims to integrate Microsoft Azure and its AI with WELL's digital health platform to enhance clinical outcomes, optimize costs, ensure data privacy, and improve scalability. The collaboration focuses on modernizing infrastructure, cost optimization, data security, and integrating innovative healthcare solutions through AI technologies. WELL aims to improve patient care, drive operational excellence, and shape the future of healthcare delivery globally.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.